Slide 1: Second Quarter Fiscal Year 2009 Conference Call
Exhibit 99.1 Simulations Plus, Inc. NASDAQ: SLP Second Quarter Fiscal Year 2009 Conference Call April 15, 2009
Slide 2: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – Second Quarter FY 2009 (2QFY09) Financial Summary – Progress in Business Units – Strategy Going Forward – Questions and Answers 2
Slide 3: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 4: 2QFY09 Financial Summary
2QFY09 Financial Summary • Gross revenues = $2.457 MM (up 12.7% from 2QFY08) - new record second quarter – Pharmaceutical software and services = $1.779 MM (up 14.8% from $1.550 MM in 2QFY08) – Words+ subsidiary = $678,000 (up 7.6% from $630,000 2QFY08) • SG&A = $1,037,000 (up 24.5% from $832,000 in
Slide 5: Share Repurchase Program
Share Repurchase Program • Board of directors authorized share repurchase program for up to $2.5 million from October 2008 through October 2009 • During 2QFY09, over 269,000 shares were bought back at average price of about $1.01/share. To date, over 386,000 shares bought back at average price per s
Slide 6: Progress - ADMET Predictor
Progress - - 1 • ADMET Predictor™ – Program was divided into modules with the last release • Requested by a number of smaller potential customers to reduce costs – appears to be a successful pricing strategy – New Dose Optimization Module developed under funded collaboration with a major pharmaceuti
Slide 7: Progress - ClassPharmer
Progress - - 2 • ClassPharmer™ – Continuing to enhance ability of ClassPharmer in data mining and de Novo molecule design (design of new molecules) – Unique “PairSAR” feature getting a lot of attention – shows pairs of molecules in a data set with very small changes in molecular structure but large
Slide 8: Progress - DDDPlus and GastroPlus
Progress - - 3 • DDDPlus™ – Sales increasing steadily, with customers now in U.S., Europe, Japan, and India, including two licenses at the FDA – Numerous improvements to new release – expected release next week – Remains the only tool of its kind • GastroPlus™ – Development of Drug-drug Interaction
Slide 9: Progress - Words+ subsidiary
Progress - - 4 • Words+ subsidiary – New Say-it! SAM™ PDA-based communication system selling well – New Conversa™ communication device selling well – Full-time national sales manager working to improve marketing and sales activities and dealer relationships – Two new employee sales reps added in Cal
Slide 10: Miscellaneous
Miscellaneous • Due diligence continues on acquisition for the pharmaceutical side of the business. Conclusion (one way or another) expected, but not assured, in the current quarter. • Director of Business Development hired – reports to Lancaster mid-May. Announcement will be made at that time • NIH
Slide 11: Strategy Going Forward
Strategy Going Forward • Continue to expand product line and services – Pharmaceutical software and services • Expand Life Sciences team by several scientists – For new product development as identified in corporate strategic planning – To increase capacity to conduct consulting studies and funded c
Slide 12: Summary
Summary • Simulations Plus financial strength continues – Excellent cash position that continues to grow – No debt – Share repurchase is gradually reducing number of shares outstanding without major impact to cash flow • Record second quarter – Pharmaceutical software and services revenues up over 1
Slide 13: Questions?
Questions? 13